Clinical trials: Resectable Pancreatic Adenocarcinoma
Pancreatic Cancer
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
The purpose of this study is to evaluate the safety and clinical activity of FOLFIRINOX along with a whole cell vaccine with immune modulating doses of cyclophosphamide and nivolumab combined with Stereotactic Body Radiation…
- Trial name
- NCT03161379
- Testing
- Cyclophosphamide, Nivolumab, GVAX Pancreas Vaccine
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Adenocarcinoma
Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency
The objective of this study is to assess weight stability, functional changes, and quality of life when Pancreaze (pancrelipase) delayed-release 84,000-lipase units (capsules), for main meals, and 42,000-lipase units (capsules)…
- Trial name
- PANCAX-3 (NCT04098237)
- Testing
- Pancrelipase
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Andrew Hendifar, MD
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
This phase II trial studies how well nab-paclitaxel and gemcitabine hydrochloride followed by radiation therapy before surgery work in treating patients with pancreatic cancer that can be removed by surgery.
- Trial name
- NCT02427841
- Testing
- Fluorouracil, Gemcitabine, Image Guided Radiation Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- OHSU Knight Cancer Institute
Pancreatic Adenocarcinoma
Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma
This is a phase II study evaluating the use of intraperitoneal gemcitabine given intraoperatively and as adjuvant therapy for patients with resectable pancreas cancer.
- Trial name
- NCT01206296
- Testing
- Intraperitoneal Gemcitabine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medstar Health Research Institute
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
This phase II trial studies how well combination chemotherapy with or without oregovomab followed by stereotactic body radiation therapy (SBRT) and nelfinavir mesylate works in treating patients with pancreatic cancer that has…
- Conditions
- Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer
- Trial name
- NCT01959672
- Testing
- 4-Dimensional Computed Tomography, Fluorouracil, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Nebraska
Pancreatic Cancer, Pancreas Cancer
Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
The purpose of this study is to see if a treatment regimen with a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and…
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma
- Trial name
- AA NABPLAGEM (NCT03410030)
- Testing
- High Dose Ascorbic Acid 25 g/m^2, Nanoparticle Paclitaxel protein bound 125mg/m^2, Cisplatin 25mg/m^2
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- HonorHealth Research Institute
Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with resectable and unresectable pancreatic cancer.
- Conditions
- Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer
- Trial name
- NCT03138720
- Testing
- Paclitaxel Protein Bound (Abraxane)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- HonorHealth Research Institute
Pancreatic Cancer
Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
This study is to determine the efficacy of bevacizumab and gemcitabine in combination with radiation therapy in the preoperative treatment of potentially-resectable subjects with pancreatic cancer.
- Trial name
- NCT00557492
- Testing
- Avastin (bevacizumab), Gemzar (Gemcitabine), external beam radiotherapy
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Amer Zureikat
Adenocarcinoma Pancreas
Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas
This study is for adult patients with adenocarcinoma of the pancreas. The purpose of this research study is to evaluate the safety and effectiveness of the drugs Gemcitabine and Abraxane in the treatment of adenocarcinoma of the…
- Trial name
- NCT01783054
- Testing
- Surgery, Genetic Expression, Chemotherapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Medical University of South Carolina
Pancreatic Cancer
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
The purpose of this study is to evaluate whether combining cyclophosphamide (CY), pembrolizumab, GVAX and IMC-CS4 is effective and safe in patients with borderline resectable pancreatic cancer.
- Trial name
- NCT03153410
- Testing
- Cyclophosphamide, GVAX Pancreas Vaccine (GVAX), Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Neoplasms
Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region
This is a single center, single arm unblinded prospective study of the safety of pancreatic stereotactic body radiation therapy (SBRT) in patients with unresectable, borderline resectable, or recurrent pancreatic/periampullary…
- Trial name
- NCT02780648
- Testing
- Stereotactic Body Radiation
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Indiana University
PDAC - Pancreatic Ductal Adenocarcinoma, FAP
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC.
- Trial name
- FAPI-46 PDAC (NCT05262855)
- Testing
- [68Ga]FAPI-46
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- SOFIE
Pancreatic Ductal Adenocarcinoma
BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this research study is to learn more about a new combination of drugs being given to treat pancreatic cancer. The drugs being tested are BMS-813160, nivolumab, gemcitabine, and nab-paclitaxel.
- Trial name
- NCT03496662
- Testing
- BMS-813160, Nivolumab, Gemcitabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
This randomized phase II trial studies how well fluorouracil, irinotecan hydrochloride, and oxaliplatin (combination chemotherapy) works and compares to gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle…
- Trial name
- NCT02562716
- Testing
- Fluorouracil, Gemcitabine Hydrochloride, Irinotecan Hydrochloride
- Where
- 807 sites in United States
- Volunteers
- 147 people
- Sponsor
- SWOG Cancer Research Network
Pancreatic Cancer
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
Surgical resection is the only potentially curative treatment for patients with pancreatic cancer. Patients with BRPC have tumors in close contact with the vasculature but not to the extent that resection is prohibited.
- Trial name
- NCT03099265
- Testing
- neoadjuvant mFOLFIRINOX, Stereotactic body radiotherapy (SBRT)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Yale University
Pancreatic Ductal Adenocarcinoma
Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma
The purpose of this study is to determine if study treatment with atezolizumab and PEGPH20 given before and after surgery, followed by chemotherapy is safe and if it can further increase the immune response against the tumor…
- Trial name
- NEOiPANC (NCT03979066)
- Testing
- Atezolizumab, PEGPH20
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Gulam Manji
Pancreatic Cancer
7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
1.1 Primary Objective To evaluate the effects of short course preoperative erlotinib treatment in a panel of predictive biomarkers from a group of patients who undergo resection of pancreatic adenocarcinoma with curative intent.
- Trial name
- NCT00841035
- Testing
- erlotinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Alabama at Birmingham
Resectable Pancreatic Ductal Adenocarcinoma
A Phase II Study of Neoadjuvant FOLFIRINOX
The primary objective of this study is to evaluate the rate of pathologic complete response to neoadjuvant FOLFIRINOX in patients with resectable pancreatic cancer using a tissue collection component.
- Trial name
- NCT02178709
- Testing
- FOLFIRINOX
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Indiana University
Pancreatic Adenocarcinoma
A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma
This is a phase II, single arm, non-randomized, open label study of liposomal irinotecan with FOLFOX in the neoadjuvant setting in patients with resectable or borderline resectable, previously untreated pancreatic adenocarcinoma.
- Trial name
- NCT03483038
- Testing
- Liposomal Irinotecan, FOLFOX regimen
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Florida
Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1…
- Trial name
- NCT03727880
- Testing
- Pembrolizumab, Defactinib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Lei Zheng